-+ 0.00%
-+ 0.00%
-+ 0.00%

Regeneron Pharmaceuticals (REGN) Wins EU Libtayo Flexibility, Is The 2% Discount Enough?

Simply Wall St·11/18/2026 04:31:49
Listen to the news

Regeneron Pharmaceuticals (REGN) is back in focus after the European Commission cleared a more flexible dosing schedule for its cancer drug Libtayo, opening the door to longer infusion intervals across multiple tumor types.

Regeneron Pharmaceuticals shares have picked up pace recently, with a 30 day share price return of 21.12% and a year to date share price return of 23.37%, while total shareholder return over the past year sits at 32.72%. This points to momentum that recent Libtayo and pipeline updates are helping to reinforce rather than reverse.

Scan other oncology and health-focused opportunities showing similar momentum by starting with our curated list of 37 healthcare AI stocks, which is aligned with the kind of pipeline progress Regeneron Pharmaceuticals is reporting.

Bulls see a deep pipeline and fresh Libtayo flexibility as justification for Regeneron Pharmaceuticals recent surge. Bears focus on a rich market value and execution risk. Which side does the current valuation lean toward as you weigh an entry point?

Most Popular Narrative: 2% Undervalued

Regeneron Pharmaceuticals closed at $957.76 against an analyst consensus fair value of $977.93, which the analyst consensus Narrative on Simply Wall St frames as a small discount supported by specific pipeline and collaboration drivers.

Regeneron Pharmaceuticals is still advancing a broad late stage pipeline in areas such as immunology, oncology, genetic medicines, and obesity. Continued readouts and regulatory decisions on these programs can add new revenue streams that support earnings growth beyond the current product portfolio.

See why 96 investors see Regeneron Pharmaceuticals as 2% undervalued.

The analyst framework uses a 7.54% discount rate and assumes revenue growth of 10.81% a year with profit margins reaching 33.61%, which together underpin the $977.93 fair value estimate. Those inputs imply only a modest gap to the current share price, so the upside case leans more on conviction in the late stage pipeline and the extended Sanofi alliance rather than on a deep valuation discount.

Result: Fair Value of $977.93 (UNDERVALUED)

Still, two pressure points could flip that 2% undervalued story if Kodiak’s retinal challenger erodes EYLEA HD strength or if Libtayo litigation escalates materially.

Find out about the key risks to this Regeneron Pharmaceuticals narrative.

Next Steps

There have been mixed messages in the Regeneron Pharmaceuticals story so far. If you want a clear view quickly, consider the 2 key rewards and 1 important warning sign.

Looking For More Investment Ideas Beyond Regeneron Pharmaceuticals?

If you stop with Regeneron Pharmaceuticals, you only see one angle. Broaden your watchlist now and give yourself more options before the next move arrives.